Evidence map›Paper›PMID 39379363›Full record

Trial reportThe pharmacogenomics journal2024

Cost analysis of CYP2C19 genetic testing in percutaneous coronary intervention patients.

Samuel Huxley, James Moriarty, Mark A Hlatky, Ryan Lennon, Kent Bailey, Malcolm Bell, Nancy Geller, Amir Lerman, Verghese Mathew, Yves Rosenberg and 4 more

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in The pharmacogenomics journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Samuel HuxleyDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0009-0002-3912-0520
James MoriartyDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Mark A HlatkyDivision of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Ryan LennonDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-8366-8422
Kent BaileyDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Malcolm BellDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Nancy GellerNational Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Amir LermanDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Verghese MathewWorldwide Network of Innovation In Clinical Education and Research (WNICER) Institute, New York, NY, USA.
Yves RosenbergNational Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Michael FarkouhPeter Munk Cardiac Centre, Heart and Stroke Richard Lewar Centre, University of Toronto, Toronto, ON, Canada.
Charanjit RihalDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Bijan BorahDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA. borah.bijan@mayo.edu.
Naveen L PereiraDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA. pereira.naveen@mayo.edu.ORCID 0000-0003-3813-3469

Funding

TAILOR PCI: Transitioning a Genotype Based Randomized Clinical Trial to a Registry Using Digital SolutionsU01HL128606 · NHLBI · MAYO CLINIC ROCHESTER · PI FARKOUH, MICHAEL E, PEREIRA, NAVEEN LUKE · 2016 to 2019
$7.0M
Clinical Implementation of Clopidogrel Pharmacogenetics: The TAILOR-PCI Trial - DCCU01HL128626 · NHLBI · MAYO CLINIC ROCHESTER · PI BAILEY, KENT R · 2016 to 2019
$1.9M
NIH HHS U01HL128606NIH HHS U01HL128626
6 · The paper itself

Abstract

CYP2C19 loss of function (LOF) carriers undergoing percutaneous coronary intervention (PCI) have an increased risk of ischemic events when treated with clopidogrel. PCI patients in TAILOR-PCI were randomized to clopidogrel or genotype-guided (GG) therapy in which LOF carriers received ticagrelor and non-carriers clopidogrel. Direct medical costs associated with a GG approach have not been described before. TAILOR-PCI participants for whom direct medical costs were available for the duration from the date of PCI to one-year post PCI were included. Primary cost estimates were obtained from the Mayo Clinic Cost Data Warehouse. There were no differences in direct medical costs between the GG and clopidogrel groups (mean $20,682 versus $19,747, p = 0.11) however total costs were greater in the GG group (mean $21,245 versus $19,891, p = 0.02) which was primarily driven by ticagrelor costs. In conclusion the increased expense of a GG strategy post PCI as compared to clopidogrel for all is primarily driven by the cost of ticagrelor.

Indexed as

ClopidogrelCytochrome P-450 CYP2C19Percutaneous Coronary InterventionPlatelet Aggregation InhibitorsTicagrelorAdenosineAgedCosts and Cost AnalysisFemaleGenetic TestingGenotypeHumansMaleMiddle AgedPharmacogenomic TestingPharmacogenomic VariantsAdenosineClopidogrelCYP2C19 protein, humanCytochrome P-450 CYP2C19Platelet Aggregation InhibitorsTicagrelorTiclopidine

Identifiers

PMID39379363

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.